JPC
PTGX icon

Jabodon PT Co’s Protagonist Therapeutics PTGX Stock Holding History

Jabodon PT Co’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-90,656
Closed -$1.61M – 40
2021
Q3 		$1.61M Buy
+90,656
New +$3.86M 0.67% 25

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Jabodon PT Co's PTGX Position: Q4 2021 in Review

Jabodon PT Co sold out of Protagonist Therapeutics (PTGX) in Q4 2021, closing a stake of 90,656 shares — an estimated $1.61M sold.

Jabodon PT Co first reported a position in PTGX in Q3 2021 and held it in 1 quarter. The position peaked at $1.61M in Q3 2021. 149 funds tracked by Wall St. Rank hold PTGX as of Q4 2021.

  • Jabodon PT Co reported no remaining Protagonist Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jabodon PT Co sold 90,656 Protagonist Therapeutics shares in Q4 2021, an estimated $1.61M.
  • Jabodon PT Co first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 1 quarter.
  • Jabodon PT Co's Protagonist Therapeutics position peaked at $1.61M in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2021.

Based on Jabodon PT Co's 13F filing for Q4 2021, filed 14 Feb 2022.